arrow
E

Emily Reisenbichler

Yale University
H指数:21
被引数:2,402

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
2023-01-0137
OAAI
Examination of low Her2 expression in breast cancer
2022-02-150
PRE
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer (vol 7, 9, 2021)
2022-02-031
OAAI
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
2021-12-0122
OAAI
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
2021-02-0845
OAAI
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
2020-09-01103
OAAI
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

更好的生物标志物之路: 风险管理框架在乳腺癌临床试验和日常实践中实施PD-L1和TILs作为免疫肿瘤学生物标志物的应用

2020-04-09143
OA
Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

在乳腺导管原位癌的前期二分组织病理学评估中,观察者之间的差异: DCISion研究

2020-03-0124
OAAI